Such efforts would aim to replicate the primary hallmarks of familial and sporadic ALS at molecular (e.g., TARDBP/TDP43 aggregation), cellular (e.g., motor neuron degeneration), and physiological levels (manifesting muscle weakness and shortened lifespan). The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.